🟢 99/100

This product looks safe

  • Vitamin B3: 40mg is 1.1× the Tolerable Upper Intake Level (35mg)
  • 44% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Vitamin B3: 40mg is 1.1× the Tolerable Upper Intake Level (35mg)

Label Data

20.4 Gram(s) Serving Size
20 Servings
Other Combinations Product Type
44% Evidence Coverage

Supplement Facts — Evidence Check

40 mg NE (250% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 1.1× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 40mg UL 35mg
5 mg (295% DV)
📊 3.8× RDA — above typical dose (UL: 100 mg) 📚 113 studies (Tier A: 3, B: 35)
RDA 1.3mg This product: 5mg UL 100mg
50 mcg (2085% DV)
📊 20.8× RDA — above typical dose 📚 138 studies (Tier A: 1, B: 44)
RDA 0.0024mg This product: 0.05mg
42 mg (10% DV)
📊 Market median: 4002.0mg (1 products) 📚 20 studies (Tier A: 0, B: 2)
This product: 42mg
Sodium
200 mg (8% DV)
10000 mg
📊 Market median: 2000.0mg (275 products)
Median 2000.0mg This product: 10000mg
BetaPower
5000 mg
4000 mg
📊 Market median: 1500.0mg (104 products) 📚 21 studies (Tier A: 0, B: 2)
This product: 4000mg
3000 mg
📊 Market median: 500.0mg (180 products) 📚 5 studies (Tier A: 0, B: 1)
This product: 3000mg
3000 mg
📊 Market median: 500.0mg (223 products) 📚 22 studies (Tier A: 0, B: 1)
This product: 3000mg
NO3-T
2000 mg
NO3-T
2000 mg
VasoDrive-AP
1000 mg
1000 mg
📊 Market median: 550.0mg (217 products) 📚 29 studies (Tier A: 0, B: 5)
This product: 1000mg
CocOganic Plus
1000 mg
✅ 1.1× RDA — within safe limits 📚 36 studies (Tier A: 1, B: 7)
RDA 550mg This product: 600mg UL 3500mg
SantEnergy Nu
400 mg
📊 Market median: 180.0mg (239 products) 📚 43 studies (Tier A: 1, B: 19)
This product: 320mg UL 400mg
Theobromine
300 mg
Nutricog
300 mg
Cognizin
250 mg
Infinergy
108.1 mg
Advantra Z
100 mg
25 mg
📊 Market median: 100.0mg (116 products) 📚 15 studies (Tier A: 0, B: 3)
This product: 25mg
Bioperine
10 mg

Other Ingredients

Malic Acid Citric Acid Silicon Dioxide Natural & Artificial Flavors Sucralose Acesulfame Potassium

Label Claims — Verification

All Other
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

⚠️ Warnings & Precautions

Allergen: Contains: Milk, coconut.

Additional Information

Servings per container: 20 40

Product Details

DSLD Entry Date 2025-01-23
Product Type Other Combinations
Form Powder
Brand Ekkovision
DSLD ID 328487
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →